Intramuscular Rabies Vaccine

As a professional manufacturer and supplier of Intramuscular Rabies Vaccines, AIM Honor's products are distributed to over 2,000 disease control centers across China, meeting diverse needs including emergency vaccination, pre-exposure prophylaxis, and cross-border procurement.  It is a benchmark in the domestic market for intramuscular rabies vaccines.

Intramuscular injection is the standard route of administration for rabies vaccines, offering core advantages such as stable absorption, good immune effect, fewer adverse reactions, and broad applicability.  Strict adherence to designated injection sites, standardized operating procedures, and immunization schedules is required.

Core Advantages of Intramuscular Injection

Intramuscular injection is the standard vaccination route for rabies vaccines. Compared with other routes, it has the advantages of stable absorption, good immune effect, and few adverse reactions:

High Absorption Efficiency: After the vaccine is injected into the muscle tissue, it can be slowly and continuously absorbed by the body, which can effectively stimulate humoral immunity and cellular immunity.

Standardized Vaccination Site: Adults and children aged ≥3 years are vaccinated in the deltoid muscle of the upper arm, and infants are vaccinated in the anterolateral thigh, which can avoid nerve and blood vessel damage.

Wide Applicable Population: There are no special contraindications, and it can be used by people of all ages.

Immunization Specifications for Intramuscular Injection

Strictly Restrict the Site: Gluteal injection is strictly prohibited to avoid the impact of adipose tissue on vaccine absorption and reduce the immune effect.

Standardize the Operation Process: The vaccine must be injected immediately after reconstitution to ensure accurate dosage, and it cannot be injected at the same site as rabies immunoglobulin.

Follow the Immunization Schedule: For post-exposure prophylaxis, the 5-dose schedule on days 0, 3, 7, 14, and 28 is adopted; for pre-exposure prophylaxis, the 3-dose schedule on days 0, 7, and 21/28 is adopted.

AIM Honor Intramuscular Rabies Vaccine: An Industry Benchmark Product

The two rabies vaccines of AIM Honor are both intramuscular injection formulations, and are the benchmarks of intramuscular rabies vaccines in China:

Mature Process and Stable EffectThe conventional vaccine has the National Drug Approval Number S20073014, with a 100% batch release qualification rate for 17 years. It adopts a lyophilization process, and becomes a clear liquid after reconstitution. It is quickly absorbed after intramuscular injection, with a 100% antibody seroconversion rate 14 days after vaccination; The serum-free vaccine is an innovative intramuscular injection formulation, adopting a serum-free high-density culture process, with potency far exceeding the Pharmacopoeia standard, and supports the WHO Simplified 4-dose Schedule, adapting to the immunization needs of different scenarios

Suitable for All Populations and Widely UsedThe products have covered more than 2000 CDC institutions across China, and can meet the diverse needs of emergency vaccination in medical institutions, pre-exposure prophylaxis for high-risk groups, and cross-border bulk procurement. It is one of the core supply products of intramuscular rabies vaccines in the world